Skip to content

Annexon ANNX Restricted Cash

Restricted Cash at other companies

Omeros logo
OmerosOMER
$1.05M0.0%
Janux Therapeutics logo
Janux TherapeuticsJANX
$816K0.0%
Alumis Inc. logo
Alumis Inc.ALMS
$86K-92.6%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2.22M+6.2%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$150K0.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's restricted cash?
Annexon (ANNX) reported restricted cash of $1.03M in Q1 2026.
How has Annexon's restricted cash changed year-over-year?
Annexon's restricted cash decreased by 0.0% year-over-year, from $1.03M to $1.03M.
What is the long-term trend for Annexon's restricted cash?
Over 4 years (2021 to 2025), Annexon's restricted cash has grown at a -3.0% compound annual growth rate (CAGR), from $1.17M to $1.03M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.